PATENT CLAIM ANALYSIS

Application Number: 15948412
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "221000"]

Abstract:
The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Claim (Index 31):
The method of claim  1 , wherein the dose of the CBD is at least 25 mg/kg/day.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 91.0
- Lexical Diversity: 1.70588
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15449177', '15449084', '15449204', '15449124', '15449185']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.865675800371753
- 35 USC 102 Novelty (BERT): 0.6190267039023466
- Combined Prediction Score: 0.8410108907248124
- Mean Citation Score: 634.6026680000001
- Max Citation Score: 636.5643
- Similarity Product: 479.6811646660924

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test